Other Events ·
On September 9, 2026, Ascendis Pharma announced Week 52 data from the open-label sentinel cohort of its reACHin Trial…
ASNDAscendis Pharma A/S
On September 9, 2026, Ascendis Pharma announced Week 52 data from the open-label sentinel cohort of its reACHin Trial for TransCon CNP (navepegritide) in infants with achondroplasia. Treatment demonstrated stabilization or improvement in foramen magnum stenosis, with a mean sagittal diameter increase of +3.15 mm and no decompression surgeries. Linear growth benefits included a mean annualized growth velocity of 9.9 cm/year and a supine length Z-score change of +0.42. The drug was generally well-tolerated with no treatment-related adverse events leading to discontinuation. Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases.